Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study()

BACKGROUND: Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated into the clinical management of patients with advanced cancer. Beyond tumor profiling, ctDNA analysis also can enable calculation of circulating tumor fraction (TF), which has previously been found to be progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Reichert, Z. R., Morgan, T. M., Li, G., Castellanos, E., Snow, T., Dall’Olio, F. G., Madison, R. W., Fine, A. D., Oxnard, G. R., Graf, R. P., Stover, D. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805517/
https://www.ncbi.nlm.nih.gov/pubmed/36208697
http://dx.doi.org/10.1016/j.annonc.2022.09.163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805517/
https://www.ncbi.nlm.nih.gov/pubmed/36208697
http://dx.doi.org/10.1016/j.annonc.2022.09.163

Ejemplares similares